Metabolic Dysfunction And Insulin Signaling Impairment Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Metabolic dysfunction and [brain insulin signaling](/entities/brain-insulin-signaling) impairment represent critical converging pathways in neurodegenerative diseases. The brain, despite comprising only 2% of body weight, consumes ~20% of glucose and oxygen, making it highly vulnerable to metabolic disturbances. Insulin signaling in the brain regulates glucose uptake, mitochondrial function, lipid metabolism, synaptic plasticity, and neuronal survival. Impairment of these pathways contributes to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and other disorders. [@cersosimo2024]
```mermaid
flowchart TD
A["Brain Insulin Resistance"] --> B["IR/IGF1R Signaling Defects"]
B --> C["PI3K/Akt/mTOR Dysregulation"]
C --> D["Impaired Glucose Uptake"]
D --> E["Mitochondrial Dysfunction"]
E --> F["Energy Failure"]
F --> G["Neuronal Death"]
B --> H["Protein Synthesis Dysregulation"]
H --> I["mTORC1 Overactivation"]
I --> J["Tau Hyperphosphorylation"]
J --> G
B --> K["Autophagy Impairment"]
K --> L["Protein Aggregate Accumulation"]
L --> G
Metabolic Dysfunction And Insulin Signaling Impairment Pathway is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Metabolic dysfunction and [brain insulin signaling](/entities/brain-insulin-signaling) impairment represent critical converging pathways in neurodegenerative diseases. The brain, despite comprising only 2% of body weight, consumes ~20% of glucose and oxygen, making it highly vulnerable to metabolic disturbances. Insulin signaling in the brain regulates glucose uptake, mitochondrial function, lipid metabolism, synaptic plasticity, and neuronal survival. Impairment of these pathways contributes to neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and other disorders. [@cersosimo2024]
| Component | Symbol | Role | Disease Association | [@srivastava2025]
|-----------|--------|------|---------------------| [@kivipelto2024]
| Insulin Receptor | IR | Binds insulin, initiates signaling | AD: reduced expression | [@cunnane2025]
| IGF-1 Receptor | IGF1R | Growth factor signaling | AD: decreased signaling | [^6]
| Insulin Receptor Substrate | [IRS-1](/entities/irs1) | Adapter protein, [Aβ](/proteins/amyloid-beta)/tau targets | AD: serine phosphorylation | [@arnold2018]
| Phosphoinositide 3-kinase | PI3K | Lipid kinase, Akt activator | AD: inhibited by [Aβ](/proteins/amyloid-beta) | [@bassil2020]
| Protein Kinase B | Akt/PKB | Survival signaling kinase | AD: reduced activity | [^9]
| Mammalian Target of Rapamycin | [mTOR](/entities/mtor) | Growth/ [autophagy](/entities/autophagy) regulator | AD: overactivated | [@chornenkyy2019]
| GLUT3 | SLC2A3 | Neuronal glucose transporter | AD: reduced expression | [@moloney2010]
| GLUT4 | SLC2A4 | Activity-dependent glucose uptake | AD: insulin-resistant | [@yarchoan2013]
Brain insulin resistance is a hallmark of AD, sometimes termed "Type 3 Diabetes." Key features include: [@odetti2003]
FDG-PET studies consistently show reduced cerebral glucose metabolism in AD: [@hoyer1998]
| Strategy | Agent Class | Examples | Status | [@zhao2009]
|----------|-------------|----------|--------|
| Intranasal Insulin | Peptide | Novolin R, Aspart | Phase II/III trials |
| GLP-1 Agonists | Peptide | Exenatide, Liraglutide | Phase II trials |
| Insulin Sensitizers | Small molecule | Thiazolidinediones | Mixed results |
| Metabolic Modulators | Cofactor | Acetyl-L-carnitine | Preclinical |
LRRK2 (leucine-rich repeat kinase 2), a major PD gene, intersects with insulin signaling:
| Drug | Target | Phase | Indication |
|------|--------|-------|------------|
| Exenatide | GLP-1R | Phase III | PD |
| Liraglutide | GLP-1R | Phase II | AD |
| AZD0328 | GLP-1R | Phase I | AD |
| Bimagrumab | ActRII | Phase II | AD |
| Biomarker | Type | Changes in Metabolic Dysfunction |
|-----------|------|--------------------------------|
| Fasting insulin | Blood | Elevated in insulin resistance |
| HOMA-IR | Calculated | Elevated indicates IR |
| CSF insulin | CSF | Reduced in AD |
| 18F-FDG-PET | Imaging | Reduced cerebral glucose metabolism |
| IRS-1 ser phosphorylation | Tissue | Increased in AD/PD brain |
The study of Metabolic Dysfunction And Insulin Signaling Impairment Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[@chornenkyy2019]: Chornenkyy Y, et al. (2019). Association of type 2 diabetes with Alzheimer's disease. Acta Neuropathol 138(5):681-693. PMID: 31338761(https://pubmed.ncbi.nlm.nih.gov/31338761/)
[@moloney2010]: Moloney AM, et al. (2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31(2):224-243. PMID: 18479832(https://pubmed.ncbi.nlm.nih.gov/18479832/)
[@yarchoan2013]: Yarchoan M, Arnold SE (2013). Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. JAMA 311(15):1565-1566. PMID: 23592080(https://pubmed.ncbi.nlm.nih.gov/23592080/)
[@odetti2003]: Odetti A, et al. (2003). Early glycosylation products in rat retina. Invest Ophthalmol Vis Sci 44(7):3106-3111. PMID: 12824259(https://pubmed.ncbi.nlm.nih.gov/12824259/)
[@hoyer1998]: Hoyer S (1998). The glucose insulin signal system and brain cognitive functions. J Neural Transm 105(4-5):415-422. PMID: 9720978(https://pubmed.ncbi.nlm.nih.gov/9720978/)
[@zhao2009]: Zhao WQ, Townsend M (2009). Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792(5):482-496. PMID: 19162252(https://pubmed.ncbi.nlm.nih.gov/19162252/)
🟡 Moderate Confidence
|-----------|-------|
| Supporting Studies | 15 references |
| Replication || Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| M
Overall Confidence: 43%
The following diagram shows the key molecular relationships involving Metabolic Dysfunction and Insulin Signaling Impairment Pathway discovered through SciDEX knowledge graph analysis: